NEMO Deficiency Syndrome

NEMO deficiency syndrome is a rare, inherited immune system disorder caused by harmful changes (variants) in the IKBKG gene on the X chromosome. IKBKG makes a protein called NEMO (NF-κB Essential Modulator), a key regulator of the NF-κB signaling pathway, which controls how cells respond to infection and inflammation. When NEMO doesn’t work properly, many immune responses are weak or misdirected, leading to serious and repeat infections, poor vaccine responses, bowel inflammation, and sometimes problems with skin, teeth, hair, and sweat glands (the “ectodermal” features). In females, certain IKBKG variants cause incontinentia pigmenti (IP); in males, “hypomorphic” (partially functioning) variants often cause EDA-ID. These conditions are all part of an IKBKG/NEMO-related spectrum. JAMA Network+3MedlinePlus+3Frontiers+3

CARASIL stands for cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. It is a very rare inherited disease that damages the tiny blood vessels in the brain. The damage causes small strokes and gradual loss of the white matter (the brain’s wiring). People often develop walking problems, mood or thinking changes, and later dementia. Many also have early hair loss and low-back pain from spine disc wear. The illness usually starts in young adulthood and slowly worsens over years. It is caused by harmful changes in the HTRA1 gene. This gene normally helps control TGF-β signaling, which keeps vessel walls healthy. When HTRA1 does not work, TGF-β signaling rises and small arteries thicken and scar, leading to brain injury. MedlinePlus

---

Another names

CARASIL is also called Nemoto disease, Maeda syndrome, and familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. All these names describe the same disorder. MedlinePlus

---

Types

There is one core disease (CARASIL) but it can look different from person to person. Doctors often describe three useful “types” by pattern, not by different genes:

1. Classic CARASIL. People have the full triad: early hair loss, low-back pain from spine disc disease, and brain small-vessel disease with strokes and leukoencephalopathy. This pattern is most often linked to two harmful HTRA1 variants (one from each parent). Frontiers+1

2. Atypical CARASIL (without alopecia or with late alopecia). Some patients lack early hair loss but still have the brain and spine problems. This has been reported in proven cases. So, absence of alopecia does not rule out CARASIL. American Academy of Neurology

3. HTRA1-related cerebral small-vessel disease (heterozygous carriers). Having one HTRA1 variant can cause an autosomal dominant small-vessel disease that overlaps with CARASIL but is usually milder (less alopecia/spondylosis, later onset). Strictly speaking this is not recessive CARASIL, but it sits on the same disease spectrum. It matters because families may show both forms. MedNexus

---

Causes

Although the root cause is HTRA1 gene damage, the list below breaks down the mechanisms, mutation types, and contributing factors that drive disease. This helps clinicians think of “causes” they can test or counsel about.

1. Biallelic HTRA1 variants (autosomal recessive). Two harmful copies are the direct cause of CARASIL. MedlinePlus

2. Loss of HTRA1 protease function. The enzyme cannot do its normal job in the vessel wall. New England Journal of Medicine

3. Excess TGF-β signaling. Signaling rises when HTRA1 is weak, leading to artery wall thickening. MedlinePlus

4. Small-artery arteriopathy. The media and adventitia of small vessels change, reducing blood flow. MedlinePlus

5. Leukoencephalopathy from chronic hypoperfusion. Poor microcirculation injures white matter. Frontiers

6. Lacunar infarcts. Small deep strokes occur as vessels occlude. Wikipedia

7. Missense mutations. Single amino-acid changes reduce HTRA1 activity. Wikipedia

8. Nonsense mutations. Premature stop codons eliminate protein production. Wikipedia

9. Frameshift or splice-site mutations. Abnormal transcripts yield nonfunctional protein. Stroke

10. Whole-gene or exon deletions (rare). Larger losses can abolish HTRA1. Frontiers

11. Founder variants in certain regions. Clusters in Japan/China suggest regional variants. MedlinePlus

12. Consanguinity. Related parents raise the chance of inheriting two bad copies. Wikipedia

13. Vascular smooth-muscle degeneration. Vessel wall cells are lost, weakening arteries. MedlinePlus

14. Extracellular matrix remodeling failure. HTRA1 normally processes matrix proteins. Stroke

15. Microangiopathy-driven inflammation signals. Vascular stress amplifies damage over time. Frontiers

16. Early spine disc degeneration. Disc changes reflect connective-tissue involvement. MedlinePlus

17. Alopecia pathway links (suspected). Abnormal TGF-β signaling may contribute to hair loss. MedlinePlus

18. Genetic heterogeneity within HTRA1. Different variants explain variable severity and features. AHA Journals

19. Overlap with dominant HTRA1-CSVD. Single-allele disease in relatives can modify the family picture. MedNexus

20. Age-related microvascular vulnerability. Symptoms often appear as small vessels age. AHA Journals

---

Symptoms

1. Gait disturbance. Walking becomes stiff or unsteady as the white matter and small deep strokes progress. MedlinePlus

2. Spasticity in legs. Muscles feel tight; reflexes are brisk; stairs become hard. MedlinePlus

3. Lacunar strokes or “stroke-like” episodes. Often before age 40, leading to stepwise decline. MedlinePlus

4. Cognitive decline. Memory and executive function fade; later dementia develops. MedlinePlus

5. Mood and personality changes. Apathy, irritability, or depression may appear early. MedlinePlus

6. Dysarthria. Speech becomes slurred from subcortical injury. Wikipedia

7. Urinary urgency or incontinence. Frontal-subcortical circuits that control bladder are affected. Wikipedia

8. Alopecia (early hair loss). Often begins in adolescence or early adulthood, though not universal. MedlinePlus+1

9. Low-back pain (lumbago). From early disc degeneration and spondylosis deformans. MedlinePlus+1

10. Neck or radicular pain. Nerve root irritation can follow disc changes. Frontiers

11. Pseudobulbar signs. Emotional lability, brisk jaw jerk, or dysphagia may develop. Wikipedia

12. Bradykinesia or parkinsonian features (sometimes). Subcortical injury can slow movement. AHA Journals

13. Headaches (variable). Some patients report headaches, often vascular in nature. AHA Journals

14. White-matter disease on MRI (a “silent” symptom). Even before severe disability. Frontiers

15. Progressive loss of independence. Most patients need help with daily living within years. MedlinePlus

---

Diagnostic tests

A) Physical exam

1. Full neurologic exam. Checks strength, tone, reflexes, sensation, speech, and coordination; looks for spastic paraparesis and pseudobulbar signs. AHA Journals

2. Gait assessment. Observes stride, speed, turns, and balance to quantify walking difficulty. MedlinePlus

3. Cognitive screening. Simple tests of attention, memory, and planning help detect early subcortical cognitive decline. MedlinePlus

4. Hair and scalp exam. Notes early alopecia (pattern and onset) as a diagnostic clue. MedlinePlus

5. Spine and musculoskeletal exam. Palpation and range-of-motion to localize discogenic low-back pain. MedlinePlus

B) Manual / bedside functional tests

6. Timed Up-and-Go (TUG). Times stand-walk-turn-sit; tracks gait decline over time. AHA Journals

7. Romberg and tandem gait. Screens balance and proprioception affected by subcortical pathways. AHA Journals

8. Spasticity scales (e.g., Modified Ashworth). Grades tone to guide therapy. AHA Journals

9. Back pain provocation tests (e.g., straight-leg raise). Suggests disc involvement from early spondylosis. MedlinePlus

10. Simple mood screen (e.g., PHQ-2/9). Checks for depression/apathy common in subcortical disease. MedlinePlus

C) Laboratory / pathological / genetic

11. Targeted HTRA1 genetic testing. Confirms biallelic pathogenic variants and secures the diagnosis. Gene panels or single-gene tests can be used. fulgentgenetics.com

12. Family genetic counseling and carrier testing. Explains autosomal recessive risk and options. MedlinePlus

13. Skin or vessel pathology (research/selected cases). Reports show loss of medial smooth-muscle cells and matrix changes in small arteries. (Biopsy is not always needed if genetics is clear.) MedlinePlus

14. Basic labs to exclude mimics. Tests (B12, thyroid, autoimmune markers, infections) help rule out other white-matter diseases; CARASIL labs are otherwise often normal. Orpha

15. CSF (rarely). Mostly to exclude inflammatory or demyelinating disorders when the picture is unclear. Orpha

D) Electrodiagnostic

16. EEG (if spells or confusion). Usually normal or nonspecific; used to exclude seizures. AHA Journals

17. EMG/NCS (selected cases). Not routine; may help if coexisting radiculopathy from disc disease is suspected. Frontiers

E) Imaging

18. Brain MRI (core test). Shows diffuse leukoencephalopathy and lacunar infarcts in deep gray/white matter; supports small-vessel disease. Frontiers+1

19. Susceptibility-weighted imaging (SWI). Looks for microbleeds common in small-vessel disorders. AHA Journals

20. MRA/CTA (when needed). Excludes large-vessel disease; CARASIL primarily affects small vessels. AHA Journals

21. Spine MRI. Reveals early disc degeneration and spondylosis deformans that cause lumbago. Frontiers

22. Cervical and lumbar radiographs (screening). May show spondylosis changes. Frontiers

23. Whole-brain diffusion imaging (DWI). Detects acute lacunar infarcts during stroke-like episodes. AHA Journals

Note: Items are grouped; a given patient will not need every study. Diagnosis is usually made with the clinical picture + brain MRI + HTRA1 genetic confirmation. MedlinePlus

Non-pharmacological treatments

1. Infection action plan & early medical review: parents/caregivers seek care at first signs of fever or cough; early evaluation prevents complications when immunity is impaired. Mechanism: reduces delay to antibiotics/IVIG adjustments. primaryimmune.org

2. Scheduled immunology follow-up: regular visits track antibody titers, IVIG dosing needs, and growth. Mechanism: proactive monitoring. primaryimmune.org

3. Vaccination strategy (avoid most live vaccines; optimize inactivated vaccines): tailor schedule and check titers. Mechanism: maximize safe protection while avoiding vaccine-associated disease. primaryimmune.org

4. Household vaccination (“cocooning”): immunize family to reduce pathogen exposure. Mechanism: herd protection at home. primaryimmune.org

5. Hand hygiene & respiratory etiquette training: cut transmission of respiratory and enteric germs. Mechanism: block exposure routes. primaryimmune.org

6. Dental care program: early pediatric dentistry, sealants, caries prevention to reduce bacterial load. Mechanism: fewer oral infection triggers. JAMA Network

7. Dermatology support for skin barrier: moisturizers, gentle cleansing, prompt care for breaks. Mechanism: restore barrier, lower infection entry. JAMA Network

8. Heat management for hypohidrosis: cool environment, hydration, cooling vests. Mechanism: prevent overheating when sweating is reduced. JAMA Network

9. Nutrition optimization: adequate calories, protein, micronutrients; dietitian input during colitis. Mechanism: supports growth and immune function. ASH Publications

10. School/childcare infection control plans: adjust attendance during outbreaks. Mechanism: exposure reduction. primaryimmune.org

11. Travel precautions: vaccines (as appropriate), masks in high-risk settings, safe food/water. Mechanism: minimize pathogen exposure. primaryimmune.org

12. Home environmental controls: smoke-free home, humidity control to protect lungs. Mechanism: reduce airway irritation/infections. primaryimmune.org

13. Physiotherapy for lungs when indicated: airway clearance if recurrent bronchitis. Mechanism: helps remove secretions and bacteria. primaryimmune.org

14. GI support for colitis: diet modifications (low-residue during flares), hydration, symptom tracking. Mechanism: reduce inflammation triggers. ASH Publications

15. Eye surveillance in IP: scheduled retina checks in infancy/childhood. Mechanism: detect treatable vascular issues early. Ovid

16. Genetic counseling for families: explain inheritance, carrier testing, reproductive options. Mechanism: informed decisions and early diagnosis. NCBI

17. Psychosocial support: coping strategies for chronic illness and hospitalizations. Mechanism: improves adherence and quality of life. primaryimmune.org

18. Infection source control at home (wound/skin care): immediate cleansing, antiseptics for minor injuries. Mechanism: reduce bacterial entry. primaryimmune.org

19. Allergy/dermatitis triggers avoidance: gentle fabrics/soaps to limit skin breaks. Mechanism: preserve the barrier. JAMA Network

20. HSCT evaluation in severe cases (non-drug but procedural): multidisciplinary assessment to decide timing and donor options. Mechanism: potential immune reconstitution. PMC+1

---

Drug treatments

Important: Most medicines below are used to manage infections or replace antibodies. The only potentially curative option for the immune defect is hematopoietic stem cell transplantation (HSCT) (covered later). Always individualize dosing with an immunologist/infectious disease specialist.

1. Immune Globulin (IVIG) – Gamunex-C/Gammaked: human immunoglobulin (IgG) replacement for primary immunodeficiency (PI); typical IV dose ~300–800 mg/kg every 3–4 weeks, or SC regimens; mechanism: supplies functional antibodies the body can’t make reliably; side-effects: headache, thrombosis risk, renal dysfunction (boxed warning), infusion reactions. U.S. Food and Drug Administration+1

2. SCIG – Hizentra: subcutaneous IgG 20% for PI; weekly or bi-weekly dosing per conversion from prior IVIG; mechanism: steady IgG levels via SC route; side-effects: local site reactions, thrombosis warning. U.S. Food and Drug Administration+1

3. HYQVIA (IG 10% + rHuPH20): facilitated SCIG enabling large-volume monthly dosing; mechanism: hyaluronidase temporarily opens tissue space to absorb IgG; side-effects: local reactions, standard Ig risks. U.S. Food and Drug Administration+1

4. Privigen (IVIG 10%): same indications as other IVIG; dosing similar to IVIG range; safety notes include thrombosis and renal warnings. U.S. Food and Drug Administration+1

5. Amoxicillin (penicillin class): oral antibiotic for common ear/sinus/chest infections; typical adult dosing 500–875 mg q8–12h; mechanism: inhibits bacterial cell wall; side-effects: allergy, GI upset. Use culture guidance to limit resistance. FDA Access Data

6. Amoxicillin-clavulanate: broader coverage for beta-lactamase producers in sinusitis/otitis; typical dosing (adult) 875/125 mg q12h; side-effects: diarrhea, liver enzyme elevations. FDA Access Data

7. Trimethoprim-sulfamethoxazole (TMP-SMX/Co-trimoxazole): prophylaxis or treatment (e.g., Pneumocystis; some bacterial infections); adult DS 800/160 mg once daily for prophylaxis (example regimen); side-effects: rash, cytopenias, renal effects. FDA Access Data

8. Azithromycin (macrolide): respiratory infection therapy and sometimes prophylaxis in bronchiectasis; typical dosing 250–500 mg depending on indication; side-effects: QT prolongation, GI upset; avoid if contraindicated. FDA Access Data

9. Fluconazole (antifungal): for candidiasis or prophylaxis in selected patients; adult doses vary (e.g., 100–400 mg daily); side-effects: hepatotoxicity, drug interactions. FDA Access Data

10. Rifampin-based combinations for atypical mycobacterial infections (specialist-directed; combination therapy mandatory). Mechanism: inhibits bacterial RNA polymerase; side-effects: hepatotoxicity, interactions. (Use per susceptibility and ID guidance.) JAMA Network

11. Clarithromycin/ethambutol combinations for nontuberculous mycobacteria where indicated; monitor vision (ethambutol). Mechanism: protein synthesis inhibition, arabinosyl transferase inhibition. JAMA Network

12. Broad-spectrum IV antibiotics (e.g., ceftriaxone, piperacillin-tazobactam) for severe sepsis per culture; dosing guided by indication and renal function; key adverse effects: allergy, C. difficile risk. (FDA-approved for multiple infections; choose per ID consult). primaryimmune.org

13. Antiviral therapy as needed (e.g., oseltamivir for influenza, acyclovir for HSV/VZV) per standard indications; mechanism: viral polymerase or DNA polymerase inhibition; usual adverse effects apply. primaryimmune.org

14. Topical ocular therapies for IP-related retinal disease are guided by ophthalmology; intravitreal agents or laser per standard care if neovascularization/ischemia occurs. Mechanism: preserve vision by treating vascular injury. Ovid

15. Anti-inflammatory GI medications (e.g., budesonide) under specialist care for colitis flares; mechanism: local steroid effect; side-effects: steroid class effects, though minimized with topical formulations. SpringerLink

16. Prophylactic antibiotics (individualized; e.g., low-dose penicillin or macrolide) in patients with frequent bacterial infections despite IgG replacement; mechanism: reduce infection frequency. primaryimmune.org

17. Adjunctive bronchodilators/mucolytics for chronic airway disease when present; mechanism: improve airflow/clearance; adverse effects per product. primaryimmune.org

18. G-CSF is sometimes used for severe neutropenia due to intercurrent conditions, not as a core NEMO therapy; mechanism: stimulates neutrophil production; adverse effects: bone pain, splenic risks. Use specialist judgment. Wikipedia

19. Avoid anti-TNF biologics unless absolutely necessary and under expert care—reports associate NEMO defects with severe mycobacterial risk when NF-κB is further blocked. Mechanism: anti-TNF suppresses key host defense. ScienceDirect

20. Peri-transplant antimicrobial/Ig protocols if proceeding to HSCT; mechanism: infection prevention during immune reconstitution; agents chosen per center protocol. PMC

---

Dietary molecular supplements

Use only as adjuncts under clinician guidance; treat deficiencies and support growth, especially with colitis or frequent infections.

1. Vitamin D (e.g., 600–1000 IU/day unless directed otherwise): supports bone/immune health; mechanism: modulates innate/adaptive immunity; monitor levels. primaryimmune.org

2. Calcium (dose per age/dietary intake): bone support in patients with low intake or steroid exposure. primaryimmune.org

3. Iron (if deficient): corrects anemia that can worsen fatigue/infection tolerance; avoid iron during active severe infection unless directed. primaryimmune.org

4. Zinc (typical 5–20 mg elemental/day depending on age): supports skin barrier and immunity; avoid excess. primaryimmune.org

5. Folate/B12 (if low): support blood cell production; lab-guided dosing. primaryimmune.org

6. Omega-3 fatty acids: may help low-grade inflammation; dosing 1–2 g/day EPA+DHA in older children/adults if approved. primaryimmune.org

7. Probiotics (strain-specific, use caution in immunodeficiency): can aid gut symptoms; discuss safety first. primaryimmune.org

8. Oral rehydration solutions during diarrhea: maintain electrolytes; mechanism: sodium-glucose cotransport. primaryimmune.org

9. Multivitamin to fill dietary gaps during illness flares. primaryimmune.org

10. High-calorie oral supplements if growth falters: support catch-up growth when intake is poor. primaryimmune.org

---

Immunity booster / regenerative / stem-cell”-type therapies

1. Hematopoietic Stem Cell Transplant (HSCT): the only intervention that can rebuild a functional immune system in severe NEMO deficiency; survival in cohorts ~74% with variability; risks include graft-versus-host disease, infection, and persistent GI inflammation in some. Dosing/conditioning is individualized. PMC+1

2. Donor selection & myeloablative/reduced-intensity conditioning: tailored transplant regimens balance engraftment with toxicity; mechanism: replace defective marrow with healthy donor stem cells. ASTCT Journal

3. Peri-transplant IVIG and antimicrobial prophylaxis: bridges immune gaps during engraftment; doses per protocol. PMC

4. Post-transplant colitis management (e.g., budesonide/infliximab in select cases): treats residual gut inflammation that may persist after immune correction. SpringerLink

5. Investigational gene therapy (future direction): correcting IKBKG has been proposed but is not established clinical care yet. Mechanism: restore NF-κB signaling by fixing the gene. ScienceDirect

6. G-CSF during marrow suppression (supportive): boosts neutrophils if critically low (not a disease-specific cure). Wikipedia

---

Surgeries/procedures

1. Central venous access device placement for recurrent IV therapies (antibiotics/IVIG); purpose: reliable access. primaryimmune.org

2. ENT procedures (e.g., tympanostomy tubes) for chronic otitis media to reduce infections and hearing loss. primaryimmune.org

3. Dental restorations/extractions/implants to manage missing or infected teeth and improve nutrition and infection control. JAMA Network

4. Ophthalmic laser/injections in IP-related retinal disease to preserve vision. Ovid

5. Hematopoietic stem cell transplantation (HSCT) as definitive immune reconstitution in severe cases. PMC

---

Preventions

1. Tailored vaccination schedule (avoid most live vaccines; optimize inactivated vaccines). primaryimmune.org

2. Household vaccines up-to-date (“cocooning”). primaryimmune.org

3. Hand hygiene and masks during viral seasons/outbreaks. primaryimmune.org

4. Prompt treatment of any suspected infection. primaryimmune.org

5. Regular IVIG/SCIG as prescribed to maintain protective IgG troughs. U.S. Food and Drug Administration

6. Dental/skin care routines to reduce entry points for germs. JAMA Network

7. Heat safety strategies if sweating is reduced. JAMA Network

8. Travel planning (vaccines as appropriate, food/water safety). primaryimmune.org

9. School/childcare alerts for outbreaks and flexible attendance. primaryimmune.org

10. Genetic counseling for family planning and early infant evaluation. NCBI

---

When to see doctors (red flags)

Seek urgent medical care for fever, fast breathing, severe cough, poor feeding, persistent diarrhea, unusual rashes or blisters, eye redness/pain, behavior changes, or dehydration—especially in infants and young children. Arrange regular immunology follow-up for lab monitoring, IgG replacement, and vaccine titers. Families with known IKBKG variants should obtain newborn evaluation for any male births and IP-like findings in females. primaryimmune.org

---

What to eat and what to avoid

1. Balanced, high-protein diet to support healing; include eggs, fish, legumes. primaryimmune.org

2. Adequate calories during/after infections; consider oral nutrition drinks if intake is low. primaryimmune.org

3. Plenty of fluids—oral rehydration during diarrhea. primaryimmune.org

4. Iron-rich foods if iron-deficient (meat, beans, fortified grains) with vitamin C for absorption. primaryimmune.org

5. Calcium and vitamin D sources for bone health (dairy, fortified alternatives, sun in moderation). primaryimmune.org

6. Omega-3 sources (fish, flax) for general anti-inflammatory support. primaryimmune.org

7. During colitis flares, low-residue choices (white rice, bananas) may ease symptoms—then gradually re-expand. SpringerLink

8. Food safety: avoid undercooked meats/unpasteurized dairy during high-risk periods. primaryimmune.org

9. Limit excess sugar and ultra-processed foods that displace nutrient-dense options. primaryimmune.org

10. Discuss probiotics before use; some are avoided in immunodeficiency. primaryimmune.org

---

FAQs

1) Is NEMO deficiency the same as incontinentia pigmenti (IP)?
They share the same gene (IKBKG/NEMO). Females with loss-of-function variants often have IP; males with hypomorphic variants often have immunodeficiency (EDA-ID). They are parts of one gene-related spectrum. NCBI+1

2) How is it inherited?
X-linked. Females may be carriers (or have IP); affected males often have immunodeficiency. Genetic counseling explains risks for each pregnancy. NCBI

3) What’s the most important lab clue?
Poor specific antibody responses to vaccines (e.g., pneumococcal), often with recurrent bacterial infections—then genetic testing confirms IKBKG. primaryimmune.org

4) Are live vaccines allowed?
Usually avoided because of infection risk and poor response; teams tailor plans individually. primaryimmune.org

5) Does IVIG cure the disease?
No. IVIG/SCIG replaces missing antibodies and lowers infection risk but doesn’t fix the gene defect. U.S. Food and Drug Administration

6) Is HSCT a cure?
HSCT can reconstitute immunity in severe cases, but outcomes vary and GI inflammation can persist in some; it carries significant risks. PMC+1

7) Why do some patients have bone or lymph swelling problems?
Certain variants (OL-EDA-ID) cause osteopetrosis and lymphedema in addition to immune problems. PubMed

8) What infections are typical?
Recurrent pneumococcal, staphylococcal, and nontuberculous mycobacterial infections, among others. JAMA Network

9) Can anti-TNF medicines be used for colitis?
They may worsen infection risk in NEMO defects; any use must be highly specialist-controlled. ScienceDirect

10) How common is it?
NEMO deficiency is rare; IP incidence is ~0.7 per 100,000 births and ~60–80% involve the exon 4–10 deletion. actasdermo.org

11) Why is genetic testing tricky here?
Because of a nearby pseudogene (IKBKGP1) that can confuse results; labs use specialized assays. Nature

12) Can girls have immunodeficiency too?
Yes—due to skewed X-inactivation or specific variants; clinical severity varies. NCBI

13) Do teeth problems matter medically?
Yes; missing/abnormal teeth can impair nutrition and increase infection risk; early dental care helps. JAMA Network

14) Are there research advances?
Ongoing studies describe new IKBKG variants and explore better testing methods; gene correction remains investigational. Nature

15) What specialists are involved?
Immunology, infectious disease, dermatology, dentistry, ophthalmology (in IP), gastroenterology, genetics, and transplant teams for severe cases. primaryimmune.org

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 10, 2025.